Physician profile
John P John
NPI 1497789507
$2,267.04
in general payments reported to CMS, 2019-2025
22 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $125 · 2021: $55.76 · 2022: $150 · 2023: $483 · 2024: $610 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.71 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $316.73 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Teva Pharmaceuticals USA, INC. | $240.05 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $220.93 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $217.31 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $213.51 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $163.63 | 2023-2024 | |
| Alkermes, INC. | $158.11 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $97.96 | 2019-2025 | Ingrezza |
| Merck Sharp & Dohme LLC | $90.77 | 2022-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $72.29 | 2019-2021 | |
| Indivior INC. | $68.43 | 2019-2022 | |
| Corium, LLC | $62.17 | 2023-2024 | Azstarys |
| Allergan, INC. | $59.98 | 2019 | |
| Ironshore Pharmaceuticals INC. | $52.71 | 2019-2020 | |
| Axsome Therapeutics, INC. | $39.77 | 2023 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $36.28 | 2019 | |
| Novo Nordisk INC | $32.75 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $32.19 | 2022-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $29.70 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $26.00 | 2022 | |
| Brainsway USA INC | $19.85 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.